NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, announced today that a team of globally renowned researchers utilized two NanoString platforms, the nCounter® Analysis System and GeoMx® Digital Spatial Profiler, to decode the immune response following the transplantation of genetically modified pig kidneys into humans. The groundbreaking study featured in the August issue and an accompanying commentary of The Lancet medical journal produced fundamental new data on the first pig-to-human organ transplants. Insight from the 2021 study contributes to the ongoing success and duration of follow-on pig-to-human transplants heralded last week in The New York Times and Wall Street Journal.
You Might Also Like
BioSkryb Genomics Partners with Research Instruments Pte Ltd to Bring Industry Leading Single-Cell Technologies to Singapore and Southeast Asia
Twist Bioscience Launches Synthetic RNA Positive Controls for SARS-CoV-2 Encapsulated in Imagene’s Stainless Steel Capsules
